German survey on telemedicine (TM) in 438 MSK patients - 63% response; showed reasons against interest in TM included: - Not yet diagnosed - No prior TM - Bad health status - Rural living - Not owning electronic device - Aged 60-80 yrs https://t.co/niO00pCuTY https://t.co/07KFNWMs1N

• https://bit.ly/3Rqsnqw

ACR Urges CMS to Reconsider Copay Assistant Programs in CMS Proposed Rule The Health and Human Services Notice of Benefit and Payment Parameters proposed rule for 2024 does not revise policies related to copay assistance and patient deductibles. https://t.co/vfXFwpGJHf https://t.co/PCa53ctowL

• https://bit.ly/3XYc7j1

For years, in my patient questionnaires, I'd ask “how high is your stress level?" Everyone said “high”, regardless of demographics. I removed “stress” from the survey, as it wasn’t a symptom; it appears the burden we carry. Read on... https://t.co/sLG3dktgRS https://t.co/oPJeQsnodR

• https://bit.ly/3WUuXWY

Feb 3rd, today is #NationalWomenPhysiciansDay. The date honors Dr. Elizabeth Blackwell, 1st woman to receive an MD United States (1849). RheumNow will devote the whole month of April 2023 to our Campaign on Women in Rheumatology - stay tuned! https://t.co/l1M56L8h9N https://t.co/eQpetW02CE

• https://bit.ly/3l5KgPc

Join us on 3/18 and 3/19 in Dallas, Texas, or virtually for RheumNow Live! Among our 24 speakers, Dr. Sergio and Monica Schwartzman will cover All in the Family Rheumatology. Dr. Philip Conaghan will cover Insights into the Future of OA and more. https://t.co/plpNqGu1HI https://t.co/mgMox5SpGN

• https://bit.ly/3HQbB0T

PNAS has a novel approach to #RA Tx; bioengineered probiotic(Lactobacillus reuteri) orally delivers a peptide Kv1.3 channel blocker to RxRA. Kv1.3 is expressed on CCR7− effector memory T cells. Blocking Kv1.3 improves RA & PSO in rat models. https://t.co/DyyXi2GUH2 https://t.co/8nDyFv9DWx

• https://bit.ly/3Y1PTwk

Deptof Veterans Affairs has awarded $1.2 million to Matlock Jeffries, MD of the Oklahoma Medical Research Foundation to study the connection between obesity, gut microbiome and cartilage changes leading to osteoarthritis of the knee. CONGRATS @matlockj https://t.co/M3807QD5K2 https://t.co/ypJNunbWWS

• https://bit.ly/3Y1V5Am

Swiss RA registry assessed outcomes after 1st JAKi. 400 RA pts starting/failing JAKi were switched to 2nd JAKi or TNFi or other MOA biologic. ~40% had prior bDMARDs. Retention was higher w/ 2nd JAK (918d)i vs other options. TNFi (335d) or OMA (918d). https://t.co/3A3KwVcTCN https://t.co/UFLPGfmzNv

• https://wb.md/3XS4sma

Herpes Zoster with JAK Inhibitors A recent review a higher HZ risk with JAKi therapy shows the HZ-risk in RA and UC to be higher than PsA when treated with usual doses of TOFA, especially those given higher TOFA doses or concomitant glucocorticoids. https://t.co/BO7CgcuRKR https://t.co/gyMivn5YxL

• https://bit.ly/3DVtid9

Is JAKi therapy safe in RA-ILD pts? Italian retrospective study (2018-June 2022) w/ 43 RA pts & HRCT proven ILD (med age 69yrs) & Rx w/ JAKi. After 19 mos F/U, the FVC was stable in 79%, improved in 11%, & worse in 11%. DLCO & HRCT trend was similar. https://t.co/bAqa5wKIYE https://t.co/LnlcQtQnm8

• https://bit.ly/3Rr6s2r

The EMAs CHMP has recommended granting a marketing authorisation for Sotyktu (deucravacitinib) for the treatment of moderate to severe plaque psoriasis in adults. https://t.co/WztKcNDFl1 https://t.co/Cq3Cyr3YqX

• https://bit.ly/3JtMv9f